With an average analyst rating of hold, Viatris is clearly not a favorite. But some of the best stock picks are contrarian in nature. With most analysts more focused on growth than on value, a mediocre analyst rating does not necessarily mean a stock is a bad investment. So what do we know about VTRS's valuation?
Over the last year, Viatris shares have moved -24.3% while trading between the prices of $8.77 and $13.55. This represents a -38.4% difference compared to the S&P 500, which moved 14.1% over the last 52 weeks.
At its current price of $9.57 per share, VTRS has a trailing price to earnings (P/E) ratio of -18.1 based on its 12 month trailing earnings per share of $-0.53. Considering its future earnings estimates of $2.67 per share, the stock's forward P/E ratio is 3.6. In comparison, the average P/E ratio of the Health Care sector is 26.07 and the average P/E ratio of the S&P 500 is 29.3.
We can also compare the ratio of Viatris's price to its book value. A company's book value refers to its present equity value: what is left when we subtract its liabilities from its assets. VTRS has a book value of 0.58, with anything close or below one indicating a potentially undervalued company.
A comparison of the share price versus company earnings and book value should be balanced by an analysis of the company's ability to pay its liabilities. One popular metric is the Quick Ratio, or Acid Test, which is the company's current assets minus its inventory and prepaid expenses divided by its current liabilities. Viatris's quick ratio is 0.819. Generally speaking, a quick ratio above 1 signifies that the company is able to meet its liabilities.
Next up in our analysis is Viatris's free cash flow, which stands at $2.42 Billion. This represents the cash that is available to the company after all of its expenses and income are accounted for -- including those that arise outside of its core business activities. This money can be used to re-invest in the business or to payout a dividend. For now, at least, Viatris has chosen the former.
At Market Inference, we will keep monitoring Viatris to see if the contrarian thesis in this stock will be vindicated. Going against the grain can be an excellent way for investors to extract value from the stock market, but it's never a good idea to apply a strategy for its own sake. Do your own research and make sure that the facts support your decision.
